Healthcare

DWHP acquires CEFALY

DW Healthcare Partners has acquired CEFALY Technology SPRL, a Belgian maker of neuro-modulating medical devices for the prevention and treatment of migraines. No financial terms were disclosed. This transaction comes on the heels of DWHP closing its fifth fund at US$610 million. Also, Jen Trainor has become CEO of CEFALY. Based in Toronto and Park City Utah, DWHP is a private equity firm focused exclusively on the healthcare industry. Currently, it is managing over US$1.4 billion in committed capital.

PE-backed Care Advantage buys Allegiance Home Care

Care Advantage, a portfolio company of BelHealth Investment Partners, has acquired Virginia-based Allegiance Home Care, a provider of in-home personal care services. No financial terms were disclosed.

Bayer AG buys BlueRock Therapeutics for $1 bln

Bayer AG has acquired BlueRock Therapeutics from Versant Ventures for up to $1 billion. BlueRock, a biotech, focuses on stem cell research.

Experian to buy MyHealthDirect

Experian said Aug. 8 that it agreed to buy MyHealthDirect. Financial terms weren’t announced. MyHealthDirect, which provides a referral management and online scheduling platform for patients, raised $27.4 million in venture funding, PitchBook said.

PE-backed Mesmerize acquires PHN

Mesmerize, a portfolio company of the Beekman Group, has acquired Pharmacy Health Network, an out-of-home digital network focused on retail pharmacies. No financial terms were disclosed.

Centerbridge walks away from ~$1.5 bln deal with GoHealth

A deal was expected to value Chicago’s GoHealth around or just south of $1.5 billion; however, the New York private equity firm ultimately pulled back due to issues around price.

Glycomine rakes in $33 mln Series B

San Carlos, California-based Glycomine Inc, a biotechnology company, has raised $33 million in Series B financing. Novo Holdings A/S led the round.

VC-backed Vor Biopharma appoints president/CEO

Cambridge, Massachusetts-based Vor Biopharma, an oncology company, has named Dr. Robert Ang as president and CEO. Ang is the former chief business officer of Neon Therapeutics. Vor Biopharma's backers include 5AM Ventures, RA Capital Management and Johnson & Johnson Innovation – JJDC Inc.

Permira in $2.4 bln buy of Cambrex

Permira has agreed to buy Cambrex Corp for $60 a share or about $2.4 billion. Cambrex, of East Rutherford, New Jersey, is a small molecule company that provides drug substance, drug product and analytical services across the entire drug lifecycle.

Sidecar Health reels in $18 mln

California-based Sidecar Health, a provider of health insurance plans, has raised $18 million in financing. GreatPoint Ventures and Morpheus Ventures led the round.